ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025)

ENDRA Life Sciences (NDRA) posted quarterly Current Deferred Revenue of $328610.0 for Q2 2025, down 15.9% sequentially from $390722.0 in Q1 2025.

ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025) Analysis & Trends

ENDRA Life Sciences has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $328610.0 for Q2 2025.

In Q2 2025, Current Deferred Revenue changed N/A year-over-year to $328610.0; the TTM figure through Jun 2025 stood at $328610.0 (changed N/A YoY), while the FY2024 annual figure was $799284.0, changed N/A from the prior year.
Current Deferred Revenue declined to $328610.0 in Q2 2025, from $390722.0 in the prior quarter.
Over the last five years, Current Deferred Revenue for NDRA reached as high as $910556.0 in Q3 2024 and fell as low as $328610.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn
10	ENDRA Life Sciences	5.95 Mn	5.59 Mn	-

Download Data